Miriam Molina Arcas

Miriam obtained her PhD in Biomedicine at the University of Barcelona in 2005. After a first postdoctoral project at the University of Barcelona, in 2008 she joined Dr. Julian Downward’s laboratory at the London Research Institute and then moved in 2016 to the Francis Crick Institute. The main aim of her research has been the identification of therapeutic strategies for the treatment of lung cancer tumours harbouring KRAS mutations. Most recently, she has focused on combination approaches that can improve the efficacy of KRAS-G12C inhibitors and reduce resistance mechanisms.